文献速递心境障碍

氯胺酮经中央杏仁核μ阿片受体神经元产生急性行为效应

Ketamine Evokes Acute Behavioral Effects Via μ Opioid Receptor-Expressing Neurons of the Central Amygdala.
PubMed 文献 · Biol Psychiatry · 2025-05-05

该研究在小鼠中筛选可被阿片受体拮抗剂逆转的氯胺酮行为效应,发现仅自主活动增加对μ阿片受体拮抗剂敏感,且中央杏仁核表达μ阿片受体与PKCδ的神经元介导该效应,提示氯胺酮急性行为作用依赖中央杏仁核μ阿片受体。

要点

  • 氯胺酮的自主活动增加效应可被μ阿片受体选择性拮抗剂阻断。
  • NMDA受体拮抗剂MK-801的自主活动增加效应不依赖阿片受体。
  • 中央杏仁核表达μ阿片受体与PKCδ的神经元介导氯胺酮急性活动效应。

核心结论

  • 氯胺酮作用于中央杏仁核表达μ阿片受体的神经元以产生急性活动增加效应。

研究设计与样本

  • 研究在雄性和雌性野生型小鼠中筛选可被阿片受体拮抗剂逆转的氯胺酮行为反应。
  • 采用全脑cFos表达成像比较氯胺酮联合纳曲酮或溶媒预处理后脑区差异。
  • 通过区域特异性药理和遗传干扰μ阿片受体信号验证行为学预测。

主要发现

  • 在多种行为学测试中,仅自主活动增加对氯胺酮敏感并可被μ阿片受体选择性拮抗剂阻断。
  • NMDA受体拮抗剂MK-801产生的自主活动增加不依赖阿片受体。
  • 全脑成像显示中央杏仁核神经元cFos表达在氯胺酮联合纳曲酮与单用氯胺酮间差异最大。
  • 中央杏仁核表达μ阿片受体与PKCδ的神经元被纳曲酮强烈激活。
  • 药理学或遗传学选择性中断中央杏仁核μ阿片受体功能可阻断氯胺酮的活动效应。

临床怎么用

  • 提示氯胺酮急性行为效应部分经中央杏仁核μ阿片受体通路介导,为理解其抗抑郁机制提供回路线索。

局限性

  • 研究为小鼠临床前实验,结果向人类精神心理科临床应用的转化需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ketamine has anesthetic, analgesic, and antidepressant properties, which may involve multiple neuromodulatory systems. In humans, the opioid receptor (OR) antagonist naltrexone blocks the antidepressant effect of ketamine. This mechanism may differentiate ketamine from other NMDA receptor antagonists. Animal models that reflect OR-dependent behavioral effects of ketamine may shed light on the brain regions and circuits that contribute to ketamine's antidepressant mechanism in humans. METHODS: We screened male and female wild-type mice for a behavioral response to ketamine that could be reversed by OR antagonists in several assays, including locomotor activation, analgesia, and the forced swim test. Whole-brain imaging of cFos expression in ketamine-treated mice, pretreated with naltrexone or vehicle, was used to identify brain areas that mediated ketamine/OR interactions. Region-specific pharmacological and genetic interference with μ OR (MOR) signaling was used to test predictions of whole-brain imaging results in a subset of behavioral assays. RESULTS: Among a series of behavioral assays, only locomotor activation was sensitive to ketamine and blocked by an MOR-selective antagonist. Locomotor activation produced by the NMDA receptor antagonist MK-801 was not OR dependent. Whole-brain imaging revealed that cFos expression in neurons of the central amygdala (CeA) showed the greatest difference between ketamine in the presence versus absence of naltrexone. CeA neurons expressing both MOR and PKCδ were strongly activated by naltrexone, and selectively interrupting MOR function in the CeA either pharmacologically or genetically blocked the locomotor effects of ketamine. CONCLUSIONS: These data suggest that ketamine acts at MORs expressed in CeA neurons to produce acute hyperlocomotion.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Pomrenze MB, Vaillancourt S, Llorach P, et al. Ketamine Evokes Acute Behavioral Effects Via μ Opioid Receptor-Expressing Neurons of the Central Amygdala. Biol Psychiatry. 2025. PMID: 40334963. doi:10.1016/j.biopsych.2025.04.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。